Literature DB >> 16169023

Valproic acid reduces enhanced vesicular glutamate transporter immunoreactivities in the dentate gyrus of the seizure prone gerbil.

T-C Kang1, D-S Kim, S-E Kwak, J-E Kim, D W Kim, J H Kang, M H Won, O-S Kwon, S-Y Choi.   

Abstract

To elucidate the relationship between glutamatergic current and vesicular glutamate transporter (VGLUT) expressions, we performed the comparative analyses of evoked potentials and VGLUT immunoreactivities in the dentate gyrus, and its response to antiepileptic drug treatments in a gerbil model. The EPSP slope that could be evoked in seizure sensitive (SS) gerbils was significantly greater than in seizure resistant (SR) gerbils. There was also a strong trend towards the larger population spike amplitude in SS gerbils. In addition, VGLUT immunoreactivities were markedly enhanced in the dentate gyrus of SS gerbils, as compared with the SR gerbils. Following valproic acid (VPA, 30 mg/kg), the population spike amplitude and the EPSP slope in response to the stimulus were markedly reduced in the dentate gyri both of SR and of SS gerbils, although this dosage of VPA had no effect in low stimulus currents in SS gerbils. Vigabatrin (VGB) and low dosage of VPA treatment did not affect the evoked responses. Similarly, VPA treatment reduced enhanced VGLUT immunoreactivities in the dentate gyrus of SS gerbils, whilst VGB did not. These findings suggest that up-regulation of VGLUT immunoreactivities may be related to the hyperexcitability of granule cells in SS gerbils, and altered VGLUT immunoreactivity in the dentate gyrus may be independent of GABAergic transmission.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16169023     DOI: 10.1016/j.neuropharm.2005.08.007

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  13 in total

Review 1.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

Review 2.  Genetic inactivation of the vesicular glutamate transporter 2 (VGLUT2) in the mouse: what have we learnt about functional glutamatergic neurotransmission?

Authors:  Asa Wallén-Mackenzie; Hanna Wootz; Hillevi Englund
Journal:  Ups J Med Sci       Date:  2010-02       Impact factor: 2.384

3.  Alterations in serotonin receptors and transporter immunoreactivities in the hippocampus in the rat unilateral hypoxic-induced epilepsy model.

Authors:  Sung-Jin An; Duk-Soo Kim
Journal:  Cell Mol Neurobiol       Date:  2011-06-17       Impact factor: 5.046

Review 4.  Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.

Authors:  Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Depress Anxiety       Date:  2011-02-24       Impact factor: 6.505

5.  Glutamatergic effects of divalproex in adolescents with mania: a proton magnetic resonance spectroscopy study.

Authors:  Jeffrey R Strawn; Nick C Patel; Wen-Jang Chu; Jing-Huei Lee; Caleb M Adler; Mi Jung Kim; Holly S Bryan; David C Alfieri; Jeffrey A Welge; Thomas J Blom; Jayasree J Nandagopal; Stephen M Strakowski; Melissa P DelBello
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-05-05       Impact factor: 8.829

6.  Vesicular Glutamate Transporter Inhibitors: Structurally Modified Brilliant Yellow Analogs.

Authors:  Jason Kehrl; J Christian Althaus; Hollis D Showalter; DiAndra M Rudzinski; Michael A Sutton; Tetsufumi Ueda
Journal:  Neurochem Res       Date:  2017-03-02       Impact factor: 3.996

7.  Comparative proteomic approach in rat model of absence epilepsy.

Authors:  Gönül Gürol; Duygu Özel Demiralp; Ayça Kasapoğlu Yılmaz; Özlem Akman; Nurbay Ateş; Ayşe Karson
Journal:  J Mol Neurosci       Date:  2014-10-17       Impact factor: 3.444

Review 8.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 9.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

10.  A new VGLUT-specific potent inhibitor: pharmacophore of Brilliant Yellow.

Authors:  Yutaka Tamura; Kiyokazu Ogita; Tetsufumi Ueda
Journal:  Neurochem Res       Date:  2013-11-19       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.